# Analysis in a murine model points to IgG responses against the 34k2 salivary

1. **proteins from *Aedes albopictus* and *Aedes aegypti* as novel promising candidate**

# markers of host exposure to *Aedes* mosquitoes

4

5

6

7

1. Sara Buezo Montero1, Paolo Gabrieli2, #a, Francesco Severini3, Leonardo Picci3, Marco Di Luca3,
2. Federico Forneris2, Luca Facchinelli4, Marta Ponzi3, Fabrizio Lombardo1, Bruno Arcà1\*

10

11

12

13

14

1. *1 Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy.*
2. *2 Department of Biology and Biotechnology “L. Spallanzani”, University of Pavia, Italy.*
3. *3 Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.*
4. *4 Department of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, UK.*
5. *#a Current Address: Department of Biosciences, University of Milan, Italy.*

20

21

22

23

1. **\*** Corresponding author
2. E-mail: bruno.arca@uniroma1.it

26

# Abstract

1. **Background.** *Aedes* mosquitoes are vectors of arboviral diseases of great relevance for public
2. health. The recent outbreaks of dengue, Zika, chikungunya and the rapid worldwide spreading of
3. *Aedes albopictus* emphasize the need for improvement of vector surveillance and control. Host
4. antibody response to mosquito salivary antigens is emerging as a relevant additional tool to directly
5. assess vector-host contact, monitor efficacy of control interventions and evaluate risk of arboviral
6. transmission.
7. **Methodology/Principal Findings.** Groups of four BALB/c mice were immunized by exposure to
8. bites of either *Aedes albopictus* or *Aedes aegypti*. The 34k2 salivary proteins from *Ae. albopictus*
9. (al34k2) and *Ae. aegypti* (ae34k2) were expressed in recombinant form and *Ae. albopictus* salivary
10. peptides were designed through B-cell epitopes prediction software. IgG responses to salivary gland
11. extracts, peptides, al34k2 and ae34k2 were measured in exposed mice. Both al34k2 and ae34k2,
12. with some individual and antigen-specific variation, elicited a clearly detectable antibody response
13. in immunized mice. Remarkably, the two orthologous proteins showed very low level of immune
14. cross-reactivity, suggesting they may eventually be developed as species-specific markers of host
15. exposure. The al34k2 immunogenicity and the limited immune cross-reactivity to ae34k2 were
16. confirmed in a single human donor hyperimmune to *Ae. albopictus* saliva.
17. **Conclusions/Significance.** Our study shows that exposure to bites of *Ae. albopictus* or *Ae. aegypti*
18. evokes in mice species-specific IgG responses to al34k2 or ae34k2, respectively. Deeper
19. understanding of duration of antibody response and validation in natural conditions of human
20. exposure to *Aedes* mosquitoes are certainly needed. However, our findings point to the al34k2
21. salivary protein as a promising potential candidate for the development of immunoassays to
22. evaluate human exposure to *Ae*. *albopictus*. This would be a step forward in the establishment of a
23. serological toolbox for the simultaneous assessment of human exposure to *Aedes* vectors and the
24. pathogens they transmit.

52

# Author summary

1. Taking advantage of several factors, as worldwide trading, climatic changes and urbanization,
2. *Aedes* mosquitoes are impressively expanding their geographic distribution. A paradigm is provided
3. by the rapid global spreading of *Aedes albopictus*, a species that is a competent vector of several
4. arboviral diseases (e.g. dengue, Zika, chikungunya) and has been responsible of quite a few
5. outbreaks in the last decade. Historically, vector control always played a pivotal role for the
6. containment of arthropod-borne diseases, and this appears especially crucial for arboviral diseases
7. for which no effective vaccines or specific medications are available. Currently, host exposure to
8. mosquitoes is indirectly evaluated by entomological methods; however, exploitation of human
9. immune responses to mosquito salivary proteins is emerging as a relevant additional tool, with
10. important epidemiological implications for the evaluation of mosquito-borne disease risk. This
11. study provides preliminary but solid indications that the 34k2 salivary proteins from *Ae. albopictus*
12. and *Aedes aegypti* may be suitable candidates for the development of serological assays to evaluate
13. spatial and/or temporal variation of human exposure to *Aedes* vectors. Combined to the presently
14. available tools to assess arboviral exposure/infection, this may be of great help for the development
15. of a serological toolbox allowing for the simultaneous determination of human exposure to *Aedes*
16. vectors and to the pathogens they transmit.

70

# Introduction

1. In the last decades *Aedes* mosquitoes have been responsible for an increased transmission
2. and severe outbreaks of arboviral diseases as dengue, chikungunya, Zika and yellow fever, creating
3. a renewed challenge for public health. Dengue viruses (DENV), with a nearly ubiquitous
4. distribution in the tropics, may be responsible for more than 100 million symptomatic infections
5. and over 20,000 deaths per year [1]. Zika virus (ZIKAV), which became widely known in 2015
6. after the epidemic emergence in Brazil, caused ~500,000 cases in 2016 and its transmission is
7. currently ongoing in at least 61 countries, mostly in the Americas but also in Western Pacific,
8. Africa and Southeast Asia [2, 3]. Chikungunya virus (CHIKV), after the major outbreak in Reunion
9. Island in 2005 [4], has caused additional epidemics in both tropical and temperate regions of the
10. world, with a very large one in 2015-2016 involving over 1 million suspected cases in the Americas
11. [5, 6]. Even the yellow fever virus (YFV), for which a safe and effective vaccine is available since
12. decades, and whose transmission has been in decline for several years, is currently endemic in 47
13. countries in Africa and Central/South America, and a modelling study estimated a disease burden of
14. at least 85,000 cases and 30,000 deaths in 2013 [7, 8]. The main vector of these arboviruses is
15. *Aedes aegypti*, however the tiger mosquito *Aedes albopictus* is gaining increasing attention due to
16. its very rapid worldwide spreading and its vector competence [9, 10]. In fact, *Ae. albopictus* can act
17. as epidemic driver in areas where *Ae. aegypti* is absent or present at low levels, as testified for
18. example by the chikungunya outbreak in Reunion Island in 2005 [4] or by the several cases of
19. autochthonous transmission of CHIKV and DENV recorded in Italy, France and Croatia from 2007
20. to 2018 [11]. Moreover, the appearance of viral mutations significantly enhancing adaptation to
21. vectors [12, 13] and the geographical spread of both these vector species due to globalization [14]
22. are raising growing concern in public health authorities. To date no specific drugs can be employed
23. to treat human cases. A dengue vaccine has recently been licensed but its use is recommended only
24. for individuals with known prior DENV infection [15], and modelling studies predict achievement
25. of cost-effectiveness only in high-transmission areas of dengue-endemic countries [16]. Therefore,
26. the main method to limit the transmission of these arboviral diseases is still to control mosquito
27. vector populations and prevent their contact with humans.
28. The evaluation of human exposure to *Aedes* mosquitoes, which is of great importance to
29. assess arboviral transmission risk and guide vector control strategies, is currently based on
30. entomological measures that provide estimates of immature and/or adult mosquito densities in a
31. defined area [17]. However, entomological indices yield an indirect assessment of human-vector
32. contact, are labor-intensive, costly, difficult to implement in some epidemiological settings (e.g.
33. low vector density) and can be applied at the community level only. Progress made in the last
34. fifteen years in the understanding of composition and complexity of blood feeding arthropod saliva
35. paved the way toward the development of novel complementary tools to directly evaluate human
36. exposure to disease vectors, with interesting implications for the improvement of vector control and
37. prediction of disease risk. In fact, while feeding on their hosts, blood sucking arthropods inject a
38. cocktail of salivary proteins whose main role is to allow for an efficient blood meal by inhibiting
39. host hemostatic and inflammatory responses [18]. Independently from its physiological role, saliva
40. of blood feeders also evokes in vertebrates an antibody response that can be exploited to evaluate
41. exposure to disease vectors; this concept was first proposed/shown for ticks [19] and then extended
42. to several other blood feeding arthropods including anopheline and culicine mosquitoes [20-22].
43. However, using mosquito saliva as antigen for immunoassays is largely impracticable for several
44. reasons. First, obtaining large amounts of saliva or salivary gland extracts (SGE) is laborious and
45. time-consuming. Second, reproducibility may be a problem, both because saliva composition may
46. vary according to mosquito physiological states and due to technical variations in the procedure of
47. saliva collection or SGE preparation. Finally, and most importantly, saliva is a mixture of several
48. dozen salivary proteins, some of which are widely spread among blood feeding arthropods, and this
49. may give rise to potential problems of cross-reactivity both at the genus and eventually even at
50. family level. However, the large amount of information made available by transcriptome studies on
51. salivary protein repertoires of blood feeding insects [23] highlighted the existence of several family-
52. and genus-specific salivary proteins, which may represent ideal candidates as markers of host
53. exposure to specific disease vectors.
54. Within the family *Culicidae*, groups of anopheline- and culicine-specific salivary proteins
55. have already been identified [24, 25] and a clear proof of concept has been provided for the gSG6
56. salivary protein from *Anopheles gambiae*. In fact, the gSG6 protein or the gSG6-P1 peptide have
57. been validated as markers of human exposure to malaria vectors in a large variety of
58. epidemiological settings in Africa [26-31]; in addition, evidence of their possible utility to evaluate
59. exposure to Asian [32] and Polynesian [33] malaria vectors has been more recently obtained. So far
60. an equally well established and widely validated marker is not available for *Aedes* mosquitoes, even
61. though very promising indications came by the exploitation of the Nterm-34kDa peptide, which is
62. designed on the culicine-specific 34k1 salivary protein from *Ae. aegypti* (reviewed in [34]). Studies
63. in exposed children from different villages in Benin [35] and in Côte d’Ivoire [36], as well as a
64. retrospective study on a population from Laos exposed to DENV [37], suggested that the Nterm-
65. 34kDa peptide may allow to detect variation in human exposure to *Ae. aegypti* bites. Moreover, the
66. IgG response to the Nterm-34kDa peptide has been employed to assess vector control
67. implementation in an urban area at La Reunion Island, where individuals were exposed to *Ae.*
68. *albopictus* and not to *Ae. aegypti*. As a consequence, it has been proposed that the IgG antibody
69. response to the *Ae. aegypti* Nterm-34kDa salivary peptide may be a relevant short term indicator to
70. evaluate the efficacy of vector control interventions against *Aedes* mosquito species [38].
71. Previous studies indicated that human antibody responses to mosquito salivary proteins are
72. heterogeneous, with some individuals responding to one antigen but not to others and with different
73. salivary proteins eliciting IgG responses that are quantitatively and qualitatively diverse [29]. In this
74. respect, the availability of more than a single salivary antigen may be very useful, especially in
75. different epidemiological settings (e.g. high versus low mosquito density), providing a better view
76. of human exposure to *Aedes* vectors and disease risk, and eventually increasing the sensitivity
77. and/or specificity of the immunoassays. Moreover, although the *Ae. aegypti* Nterm-34kDa peptide
78. was successfully used to evaluate exposure to *Ae. albopictus* [38], the N-terminal region of the 34k1
79. protein is relatively divergent in these two species (12 identical residues over 19 with a 3 amino
80. acids gap), suggesting that the availability of markers based on *Ae. albopictus* salivary proteins may
81. provide some advantages. In the present study the suitability of novel candidate salivary markers of
82. host exposure to *Aedes* mosquitoes was evaluated in an experimental model where mice were
83. subjected to a controlled regimen of exposure to bites of *Ae. albopictus* or *Ae. aegypti*. In addition,
84. an hyperimmune serum from a human volunteer was used to provide some preliminary but valuable
85. indication on the antigenicity to humans of the recombinant 34k2 salivary protein from *Ae.*
86. *albopictus*.

# Methods

## Ethical statement

1. According to D.lgs 26/2014, which has transposed in Italy the European [Directive](http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32010L0063)
2. [2010/63/EU](http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32010L0063) on the protection of animals used for scientific purposes, the animal research protocol
3. has been reviewed and approved by the Animal Welfare Body of the Istituto Superiore di Sanità
4. (Italian National Institute of Health) and authorized by the Italian Ministry of Health with
5. authorization number 150/2016-PR of 19th February 2016. The human serum employed in this
6. study was provided from a single donor who, for his own purposes (colony maintenance) and
7. independently from this study, had regularly fed an *Aedes albopictus* colony. This hyperimmune
8. healthy adult donor provided written informed consent for the use of the serum to measure IgG
9. antibody levels against mosquito salivary proteins. No formal request for approval on the use of this
10. serum, which was provided by the hyperimmune donor on a pure voluntary basis, was submitted to
11. the authors’ institutional review board or equivalent committee.

## Mosquito rearing and salivary gland extracts preparation

1. *Aedes albopictus* (originally collected in Rome, Italy) and *Ae. aegypti* (originally collected
2. in Reynosa, Mexico) were reared in the insectary of Sapienza University of Rome and Istituto
3. Superiore di Sanità under standard conditions (27 ± 1°C, 70% relative humidity, 14:10 hours
4. light:dark photoperiod) and colony maintenance achieved by feeding on guinea pigs or by
5. membrane feeding using rabbit blood. Adult female mosquitoes 3-8 days post-emergence (dpe), and
6. never fed on blood before, were used for all the experiments. Mosquitoes were starved for at least
7. 6-8 hours before exposure to mice. Salivary glands were dissected in Phosphate Buffered Saline
8. (PBS), transferred into a tube containing 20 µl of PBS and frozen at -80°C in batches of 20-40
9. salivary glands. Salivary gland extracts (SGE) were prepared by three cycles of freezing and
10. thawing followed by centrifugation at 16,000 x g at 4°C. Supernatants were collected and protein
11. concentration measured by the Bradford method (Bio-Rad Laboratories Inc., USA) after pooling the
12. different batches in order to generate a homogeneous SGE stock to be used for all ELISA assays.
13. Protein concentration was determined using the Take3 micro-volume plate in a BioTek microplate
14. reader (BioTek Synergy HT). SGE stocks were aliquoted and stored at -20oC until use.

## Mice immunization and sera collection

1. Female BALB/c mice, aged 6-8 weeks were obtained from Charles River Laboratories and
2. kept in the animal facility of Istituto Superiore di Sanità according to approved Institutional Animal
3. Care and Use Committee protocols. Two cohorts, composed of 4 naïve mice each, were
4. anesthetized and exposed to bites of either *Ae. albopictus* or *Ae. aegypti*. Briefly, the abdomen of
5. each mice was exposed for ~20 minutes to one of four paper cups covered with a mesh net
6. containing 33-47 adult female mosquitoes (either *Ae. albopictus* or *Ae. aegypti* ) per mice. All mice
7. were exposed on the same day every 2 weeks for 6 weeks (total 4 times), an exposure regimen
8. similar to those previously employed for immunization to anopheline mosquito saliva [39, 40]. The
9. number of mosquitoes who successfully fed on each mouse following each exposure is reported in
10. Supplemental Table S1. An additional group of mice not exposed to any mosquito was also
11. included in the experimental plan as a further control. Small blood aliquots (~50-100 µl) were
12. collected from the tail vein for serum preparation at different time points: one week before the 1st
13. exposure (B, baseline), one week after the 2nd exposure (M, midterm), one week after the 4th/last
14. exposure (T, top) and then 1, 2 and 3 months after the end of the exposure regimen (+30, +60 and

204 +90, respectively). Finally, 5 months after the last exposure (+150) mice were sacrificed and larger

1. blood volumes (> 600 µl) collected by cardiac puncture. After blood clotting sera were separated by
2. centrifugation at 10,000 g for 15 minutes and stored at -20°C.

## Human hyperimmune serum

1. An hyperimmune serum was obtained in February 2013 from a volunteer who had been
2. regularly feeding, for his own purposes (colony maintenance) and independently from this study, an
3. *Ae. albopictus* colony fortnightly in the previous 4 months. Thirty-nine months later, in May 2016,
4. a second serum aliquot was obtained from the same donor who had not been feeding *Ae. albopictus*
5. nor other *Aedes* spp colonies for at least twenty-four months and had eventually only natural
6. exposure to *Aedes* mosquitoes. Written informed consent for participation to this study was
7. provided from the volunteer.

## Peptide design

1. Peptides were designed on *Ae. albopictus* salivary proteins previously identified as restricted
2. to culicine mosquitoes [25, 41, 42] and exhibiting limited amino acid identity (<50%) to *Culex*
3. species. Potentially immunogenic peptides were selected using four different bioinformatic tools for
4. the prediction of B-cell epitopes and immunogenic regions: BepiPred [43], ABCpred [44], Bcepred
5. [45] and Epitopia [46, 47]. Five peptides 21-23 amino acids in length were designed on three *Ae.*
6. *albopictus* salivary proteins and chemically synthesized by Biomatik Corporation (Canada):
7. alb34k1-P1 (HPLPEEATSDAAIKCTLSEED), representing the N-terminus of the 34k1 protein
8. ([AAV90689](https://www.ncbi.nlm.nih.gov/protein/AAV90689)); alb34k2-P2 (TVSEEDLTTIRNAIQKASRASLD) and alb34k2-P3
9. (ALKFYPKTGNKEANEADIRGRQF), designed in the N- and C-terminal regions of the 34k2
10. salivary protein ([AAV90690](https://www.ncbi.nlm.nih.gov/protein/AAV90690)); alb62k1-P4 (LTHIEKPIYTEEAESETSDSDE) and alb62k1-P5
11. (YGLSGMRSGGIPDNHAEWKLNA) designed in the N- and C-terminal regions of the 62k1
12. protein ([AAV90683](https://www.ncbi.nlm.nih.gov/protein/AAV90683)) .
13. **Expression and purification of the *Ae. albopictus* and *Ae. aegypti* 34k2 salivary proteins**
14. The sequence encoding for the mature *Ae. albopictus* 34k2 protein (mRNA [AY826118](https://www.ncbi.nlm.nih.gov/nuccore/AY826118),
15. protein [AAV90690](https://www.ncbi.nlm.nih.gov/protein/AAV90690)) was obtained by cDNA synthesis followed by PCR amplification. Briefly, total
16. RNA was extracted from salivary glands of *Ae. albopictus* females (6 dpe) using the TRIzol reagent
17. (ThermoFisher Scientific) and cDNA synthetized by the iScript cDNA synthesis kit (Bio-Rad). The
18. region encoding for the mature protein was amplified using the high-fidelity Platinum Pfx DNA
19. polymerase (ThermoFisher Scientific) and the primers 5’-
20. AGTCGGATCCAACCCAACCCCAAAGTCG-3’ (forward) and 5’-
21. CGTAGCGGCCGCTATTACAATGTACCCCTTAAGCCC-3’ (reverse) carrying *Bam*H I and *Not*
22. I restriction sites. The PCR product was first cloned into the PCRII TOPO TA vector
23. (ThermoFisher Scientific) and then directionally subcloned into a modified pETSUMO vector
24. (Invitrogen), which allows for the expression of recombinant proteins fused at their N-terminus to a
25. 8xHis-tag and SUMO protein in order to help purification and increase solubility, respectively [48].
26. The sequence encoding the mature *Ae. aegypti* 34k-2 protein (mRNA [AF466595](https://www.ncbi.nlm.nih.gov/nuccore/AF466595), protein
27. [AAL76018](https://www.ncbi.nlm.nih.gov/protein/18568296)) was purchased from GENEWIZ UK as synthetic gene, codon-optimized for
28. *Escherichia coli* expression, and subcloned into the modified pETSUMO vector. Recombinant
29. proteins were expressed in the T7 SHuffle *E*. *coli* K12 strain (New England Biolabs). Pre-cultures
30. from a single colony were grown overnight at 30°C in 100 ml of LB medium supplemented with 50
31. g/ml kanamycin in a 500 ml flask. One liter of preparative scale cultures in autoinducing medium
32. ZYP5052 [49] were inoculated with 50 mL of the overnight pre-culture and grown at 30°C for 4.5
33. hours. The temperature was then set at 20°C and cultures were let grow overnight. Cells were
34. harvested at 3000 *g*, resuspended in buffer A (25 mM HEPES, 500 mM NaCl, pH 8.0) and lysed by
35. sonication. The cleared lysate, obtained after centrifugation at 75000 *g* for 45 minutes at 4°C, was
36. loaded onto a HisTrap excel column (GE Healthcare) using an Äkta system (GE Healthcare) at
37. room temperature. Protein elution was performed with buffer B (25 mM HEPES, 500 mM NaCl,
38. 250 mM imidazole, pH 8.0). The eluted sample was incubated with His-tagged SUMO protease and
39. dialyzed overnight in buffer A at 4°C. After removal of His-SUMO tag and His-SUMO protease
40. through a second passage on the HisTrap column, the sample was concentrated using Vivaspin
41. Turbo 15 filters (Sartorius, MWCO 10 kDa) and loaded onto a Superdex 75 10/300 GL column
42. equilibrated in 25 mM HEPES, 100 mM NaCl, pH 8.0. Protein concentration was evaluated
43. determining the absorbance at 280 nm and assuming, according to the Expasy ProtParam tool [50],
44. extinction coefficients of 0.82 and 0.84 for the *Ae. albopictus* and the *Ae. aegypti* protein,
45. respectively. Purified proteins were concentrated and stored at -80 °C until usage.

## Enzyme-linked immunosorbent assays and data analysis

1. Enzyme-linked immunosorbent assays (ELISA) were essentially performed as previously described
2. for the *An. gambiae* gSG6 protein [51]. Briefly, coating was performed in 50µl of Coating Buffer
3. (15mM Na2CO3, 35mM NaHCO3, 3mM NaN3, pH 9.6) for 3 hours at room temperature in 96-well
4. plates (Nunc Maxisorp) using 20 µg/ml of peptides or 5µg/ml of purified recombinant proteins
5. (al34k2 and ae34k2). Salivary gland extracts (SGE) were used at a concentration of 10 SG/ml (i.e.
6. the equivalent of 10 salivary gland protein extract per ml), which corresponded to 8.6 µg/ml for *Ae.*
7. *albopictus* and 11.0 µg/ml for *Ae. aegypti*. Plates were: (i) blocked for 3 hours at room temperature
8. (150 µl 1% w/v skimmed dry milk in PBST); (ii) incubated overnight at 4oC with 50µl of a 1:50
9. dilution of sera; (iii) incubated for 3 hours at room temperature with 100µl of a goat anti-mouse IgG
10. horseradish peroxidase-conjugated antibody (Pierce 31430, 1:10000 dilution); (iv) incubated in the
11. dark at 25oC for 15 minutes with 100µl of o-phenylenediamine dihydrochloride (OPD, Sigma
12. P8287) for colorimetric development. Reactions were terminated by adding 25µl of 2M H2SO4.
13. Three to four washings were performed between each step. OD492 were determined using a
14. microplate reader (Biotek Synergy HT). All samples were analyzed in duplicate with the antigen
15. and once with no antigen. The no antigen well was used for background subtraction and results
16. were expressed as ΔOD values, which were calculated according to the formula ΔOD = ODX –
17. ODN, where ODX represents the mean of the duplicate with the antigen and ODN the value in the
18. well without antigen. Negative and positive controls were included to control for intra- and inter-
19. assay variation, which was always below 20%. Graph Pad Prism Software (San Diego, CA USA)
20. was used for graph preparation.
21. The tentative estimation of cross-reactivity was made taking into account ΔOD levels
22. measured in mice sera at four different time points: T (fully developed response), +30, +60 and +90
23. (possible start of declining). For each *Ae. albopictus*-exposed mouse and time point the ratio
24. between the IgG responses to aeSGE and alSGE was considered, and the mean values among the
25. four mice for each time point calculated. The mean value among the four time points was 0.60
26. (range 0.55-0.64). A similar calculation was made for *Ae. aegypti*-exposed mice considering the
27. ratio between ΔOD levels alSGE/aeSGE, which yielded a mean value among the four time points of
28. 0.41 (range 0.34-0.47). Combining these results a rough provisional estimation of the level of
29. immune cross-reactivity of SGE from these two species in our experimental mice could be of
30. approximately 50%.

# Results

1. **Mice immunization by exposure to *Aedes albopictus* and *Aedes aegypti***
2. To evaluate the immunogenicity of candidate peptides and recombinant proteins we first
3. immunized groups of 4 naïve BALB/c mice by exposure to bites of *Ae. albopictus* or *Ae. aegypti*.
4. Overall, blood feeding efficiency was unexpectedly higher for *Ae. aegypti* (80.6%) than for *Ae.*
5. *albopictus* (49.6%), with an average of 28 and 21 fed mosquitoes/mouse/exposure, respectively
6. (Table 1). Small blood aliquots (~50-100 µl) were collected at different time points as described in
7. the Method section.

## Table 1. Mean number of mosquitoes and percentage feeding

|  |  |  |  |
| --- | --- | --- | --- |
|  | mosquito n | fed n | fed % |
| *Ae. albopictus* | 44 (41.5-47.0) | 21 (17.8-24.0) | 49.6 (42.6-57.8) |
| *Ae. aegypti* | 35 (33.0-37.5) | 28 (25.5-30.3) | 80.6 (74.1-86.8) |

1. Number of mosquitoes and percentages represent the mean per mouse per exposure. Ranges are in brackets.
2. Mice immunization was verified measuring by ELISA the IgG responses to salivary gland
3. extracts (SGE) of the corresponding mosquito species. All mice exposed to *Ae. albopictus*
4. developed an antibody response to alSGE, with anti-saliva IgG levels increasing after the second
5. exposure, reaching a peak one week after the fourth/last exposure and remaining essentially
6. unchanged up to 3-5 months post-exposure (Fig 1A). A similar pattern was found in mice exposed
7. to *Ae. aegypti*, even though IgG levels against aeSGE appeared higher in most mice (Fig 1B).
8. Overall, independently from inter-individual and inter-species quantitative differences, these
9. observations indicate that the exposure regimen was effective both for *Ae. aegypti* and *Ae.*
10. *albopictus*, with all mice developing anti-SGE IgG responses.
11. The salivary proteins of *Ae. albopictus* and *Ae. aegypti* were estimated to share, on average,
12. ~70% amino acid identity [41]; therefore, we wondered if mice exposed to *Ae. albopictus* could
13. recognize aeSGE and vice versa. Not surprisingly, IgG raised by exposure to saliva of one species
14. could recognize SGE from the other species (Fig 1C and 1D), indicating a certain degree of cross-
15. reactivity due to the common and relatively conserved repertoire of salivary proteins [23, 41, 42].
16. **Fig 1 Anti-SGE IgG responses of mice exposed to bites of either *Ae. albopictus* or *Ae. aegypti* .**
17. IgG responses of *Ae. albopictus*-exposed mice to SGE from *Ae. albopictus* (alSGE) and from *Ae.*
18. *aegypti* (aeSGE) are shown in panels A and C, respectively. IgG responses of *Ae. aegypti*-exposed
19. mice to aeSGE and alSGE are reported in panels B and D. IgG levels are expressed as OD values
20. at 492 nm. The response of the individual mice is in color as reported in the legends. Thick black
21. lines represent mean OD values, bars denote standard errors. The different time points are as
22. follows: B = baseline, one week before exposure; M = midterm, one week after the second
23. exposure; T = top, one week after the fourth and last exposure; +30/+60/+90/+150, 30/60/90/150
24. days post-exposure.
25. **Selection of candidate *Ae. albopictus* salivary proteins and peptide design**
26. As a first approach toward the identification of candidate salivary antigens for the
27. development of immunoassays to evaluate host exposure to *Ae. albopictus* we decided to try the
28. design of peptides, which could be tested using sera from the immunized mice. Noteworthy,
29. peptides designed on mosquito salivary proteins, namely the gSG6-P1 and the Nterm-34kDa
30. peptides, have been already successfully used to assess human exposure to *Anopheles* [27, 52-54]
31. and *Aedes* vectors [35, 38], respectively. Therefore, a group of *Ae. albopictus* salivary proteins were
32. selected (i) on the basis of culicine-specificity, i.e. their absence in the saliva of anophelines or
33. other blood feeding arthropods [25, 41, 42], (ii) according to their limited identity (< 50%) to
34. homologs from *Culex* species and (iii) taking also into account previous indications of
35. immunogenicity [55]. Considering only peptides whose antigenicity was predicted by multiple tools
36. we ended up with five candidates from three different *Ae. albopictus* proteins: 34k1 ([AAV90689](https://www.ncbi.nlm.nih.gov/protein/AAV90689))
37. and 34k2 ([AAV90690](https://www.ncbi.nlm.nih.gov/protein/AAV90690)), both members of the 34 kDa salivary protein family, and the
38. 62k1([AAV90683](https://www.ncbi.nlm.nih.gov/protein/AAV90683)) protein, belonging to the 62 kDa family. Members of both these protein families
39. are found exclusively in *Aedes* mosquitoes, are highly enriched or specifically found in adult female
40. salivary glands [41, 42] and, notably, were previously shown to be immunogenic to humans [55].
41. The physiological role of the 34 kDa and 62 kDa salivary proteins in blood feeding is presently
42. unknown, however the 34k1 *Ae. aegypti* protein was found to enhance DENV replication in human
43. keratinocytes [56] and its silencing in the mosquito by RNAi reduced DENV2 replication in the
44. salivary glands [57]. The first peptide, alb34k1-P1 (21 amino acids) is designed on the N-terminus
45. of the *Ae. albopictus* 34k1 protein in a position corresponding to the Nterm-34kDa salivary peptide
46. (19 amino acids) designed on the *Ae. aegypti* ortholog [35]. The four remaining peptides alb34k2-
47. P2, alb34k2-P3, alb62k1-P4 and alb62k1-P5 were designed in the N- and C-terminal regions of the
48. 34k2 and 62k1 salivary proteins, respectively.
49. IgG responses to these peptides were analyzed by ELISA in mice immunized to *Ae.*
50. *albopictus* or *Ae. aegypti* saliva. However, even using low sera dilutions (1:20) and high peptide
51. concentrations (20 µg/ml), and also mixing together the five peptides, no response was observed in
52. any mice. IgG responses to the peptides were also analyzed in the same conditions using a human
53. serum from a donor hyperimmune to *Ae. albopictus* saliva but no IgG recognizing the peptides
54. could be revealed.
55. **Expression of recombinant 34k2 salivary proteins from *Ae. albopictus* and *Ae. aegypti***
56. As a second parallel approach, the expression in recombinant form of a few candidate
57. salivary proteins from *Ae. albopictus*, including the 62k1 and 62k2 proteins, was attempted.
58. Specifically, conditions for expression and purification of the *Ae. albopictus* 34k2 salivary protein,
59. for which previous indication of immunogenicity were available [55], were optimized. The 34 kDa
60. family of salivary proteins was originally identified in *Ae. aegypti* and found to be composed by at
61. least three members, two of which, named 34k1 ([ABF18170](https://www.ncbi.nlm.nih.gov/protein/ABF18170)) and 34k2 ([AL76018](https://www.ncbi.nlm.nih.gov/protein/AAL76018)), are abundant in
62. saliva and enriched or specifically expressed in adult female salivary glands [42]. Two family
63. members, orthologs of the *Ae. aegypti* 34k1 and 34k2 and with a similar expression profile, were
64. found in *Ae. albopictus* [41]. Among Metazoan, proteins of the 34kDa family are only found in
65. culicine mosquitoes and, due to the intron less nature of their genes, it has been suggested they may
66. have been acquired by horizontal transmission. Orthologs between the two *Aedes* species share 65%
67. (34k1) and 62% (34k2) amino acid identity, whereas paralogs exhibit 32-33% identity. Members of
68. the 34kDa family appear to be present also in *Culex* species [58, 59], however they are only
69. distantly related to the *Aedes* proteins (23% to 28% identity). We will refer to the *Ae. albopictus*
70. and *Ae. aegypti* 34kDa proteins as al34k1/2 and ae34k1/2, respectively. The al34k2 protein was
71. successfully expressed in *E.coli* and purified to homogeneity and, after some initial tests indicating
72. its immunogenicity, also the ae34k2 salivary protein from *Ae. aegypti* was expressed/purified in a
73. similar manner (Fig 2).
74. **Fig 2. Purification of the *Ae. albopictus* and *Ae. aegypti* 34k2 recombinant proteins.** Size
75. exclusion chromatograms (Superdex-75 10/300 GL, GE Healthcare) showing the peaks (shaded)
76. corresponding to the pure *Ae. albopictus* (A) and *Ae. aegypti* (B) 34k2 salivary proteins. Fractions
77. corresponding to the peaks were pooled, analysed by SDS-PAGE on a Mini-Protean TGX Stain-
78. free precast gel in non-reducing conditions and stained with Coomassie Brilliant Blue R-250 (C).
79. M, Molecular Weight Marker; 1, al34k2; 2, ae34k2.
80. **IgG responses to the *Ae. albopictus* and *Ae. aegypti* 34k2 salivary proteins**
81. IgG antibody levels against the al34k2 and ae34k2 were measured by ELISA in mice
82. exposed to bites of *Ae. albopictus* or *Ae. aegypti*, respectively. Two out of four *Ae. albopictus*-
83. exposed mice (M10 and M12) showed IgG responses to al34k2. In both mice the response reached
84. a peak one week after the last exposure and was stable up to 2 months after the end of the exposure
85. regimen. The response then decreased gradually in M10 and, instead, persisted or even had some
86. increase in M12. No anti-al34k2 IgG responses were detectable in the other two mice (M9 and
87. M11) at any time point (Fig 3A). As far as the *Ae. aegypti*-exposed mice are concerned, all mice
88. exhibited IgG responses to ae34k2, although at a different degree and with slightly different kinetics
89. (Fig 3B). The response reached a peak one week to one month after the last exposure and then
90. stayed unchanged in M5 and M8, continued to slightly increase in M7 and showed a trend to
91. decrease in M6. These results indicate that, despite some inter-individual variability, both al34k2
92. and ae34k2 are immunogenic to mice. The higher IgG levels and the responses of all *Ae. aegypti*-
93. exposed mice may be due to the more effective immunization to saliva achieved in these mice
94. (likely because of the higher number of bites/mouse/exposure) as also indicated by the IgG
95. responses to SGE (Fig 1). Interestingly, considering the relatively high conservation of the 34k2
96. proteins in the two *Aedes* species, no immune cross-reaction was observed. Indeed, IgG antibodies
97. directed against al34k2 could not recognize the *Ae. aegypti* protein and, conversely, anti-ae34k2
98. IgG did not recognize the *Ae. albopictus* protein (Fig 3, C and D). These observations suggest that
99. the 34k2 proteins from *Ae. aegypti* and *Ae. albopictus* may represent interesting species-specific
100. markers to evaluate host exposure to these two *Aedes* species.
101. **Fig 3. IgG responses to al34k2 and ae34k2 of *Ae. albopictus*- and *Ae. aegypti*-exposed mice.**
102. Anti-al34k2 (A) and anti-ae34k2 (C) IgG levels in *Ae. albopictus*-exposed mice. IgG responses of
103. *Ae. aegypti*-exposed mice to ae34k2 and al34k2 are shown in (B) and (D), respectively. Time points
104. as in Figure 1.
105. The availability of a single human serum hyperimmune to *Ae. albopictus* saliva offered the
106. opportunity to obtain some preliminary indication on the immunogenicity to humans of al34k2, and
107. eventually on the immune cross-reactivity to ae34k2. The human serum was obtained from a donor
108. at two different time points: (i) in February 2013 (T1), after feeding for a period of approximately
109. four months an *Ae. albopictus* colony, and (ii) in May 2016 (T2), after the volunteer had not been
110. feeding *Ae. albopictus* nor other *Aedes* spp colonies for at least two years (and had, likely, only
111. natural exposure to *Aedes* mosquitoes). An intense IgG response against both alSGE and aeSGE
112. was detectable at T1, confirming the hyperimmunization of the donor against *Ae. albopictus* saliva
113. and displaying a wide IgG cross-reactivity to SGE from *Ae. aegypti*. On the contrary, the IgG
114. response to al34k2 appeared considerably higher as compared to the response to ae34k2 (Fig 4). At
115. the time point T2 the IgG response to both alSGE and aeSGE persisted, even though at a slightly
116. lower level. On the contrary, the specific IgG response to al34k2 had a remarkable decrease and
117. also levels of anti-ae34k2 IgG appeared reduced. Overall, despite the obvious intrinsic limitations
118. due to the availability of a single human serum and by the hyperimmune status, these observations
119. suggest that al34k2 is immunogenic to humans and that, as observed in mice, there may be a limited
120. cross-reactivity to the two orthologous 34k2 proteins.

## Fig 4. Levels of anti-SGE and anti-34k2 IgG in a human hyperimmune serum. Levels of IgG

1. antibodies directed against alSGE, aeSGE, al34k2 and ae34k2 were determined at two different
2. time points: (i) T1 (2013), shortly after regularly feeding an *Ae. albopictus* colony approximately
3. every two weeks for 4 months; (ii) T2 (2016), after the donor had not been feeding *Ae. albopictus*
4. nor other *Aedes* spp colonies for at least two years.

# Discussion

1. Toward the development of immunoassays based on vector salivary proteins to assess
2. human exposure to *Aedes* mosquitoes, we report here the use of a murine model to test candidate
3. peptides and recombinant salivary proteins from *Ae. albopictus* and *Ae. aegypti*. The choice of an
4. experimental animal model, despite intrinsic limitations as the need for downstream validation in
5. humans, has the advantage to allow the setting of strictly controlled conditions of exposure and,
6. possibly, to provide valuable information on the kinetics of mounting/decay of the humoral
7. response and eventually on its species-specificity. The regimen of mice exposure was previously
8. successfully used for mice immunization by exposure to anopheline mosquitoes [39, 40] and the
9. candidate salivary proteins analyzed in our study were already known to be culicine-specific, absent
10. in the saliva of anopheline mosquitoes and not encoded in their genomes [24, 25]. The protocol of
11. exposure was effective for both *Ae. albopictus* and *Ae. aegypti*: in both cases all exposed mice, with
12. some individual variation, carried in their sera relatively high levels of IgG antibodies against SGE
13. from the same species. The anti-SGE IgG response could be detected in most mice already after the
14. second exposure but the peak was reached only after the fourth and last exposure. Although the
15. absence of later time points does not allow to clarify in more detail the kinetics, the mice anti-saliva
16. IgG responses were essentially stable up to 3 months later, with some apparent decline in half of the
17. immunized mice 5 months after the end of exposure (Fig 1A-B). Although several studies
18. investigated the effects of mosquito saliva on host immune cells and/or on arboviral transmission, to
19. our knowledge a detailed analysis of development and decay of mice IgG responses to *Aedes* saliva
20. or salivary proteins has not been previously performed. However, it is pretty well established that in
21. conditions of natural exposure the human IgG antibody response against mosquito saliva
22. progressively declines after termination or drastic reduction of the exposure, even though the
23. specific timing may depend by several factors such as age and history (intensity and persistence) of
24. exposure. As far as *Aedes* mosquitoes are concerned, a decreased IgG antibody response against *Ae.*
25. *aegypti* saliva was reported in French soldiers three months after their return from a travel period in
26. tropical Africa [60], and similar results were obtained in Colombians coming back to an *Ae.*
27. *aegypti*-free area after travelling to DENV endemic areas [61]. Also, a significant reduction of IgG
28. levels against *Ae. albopictus* saliva was found already six weeks after the implementation of vector
29. control interventions in La Reunion Island [62]. A decrease in the response against alSGE was also
30. observed in the hyperimmune donor between time points T1 and T2, although high anti-alSGE IgG
31. levels still persisted at T2, that is three years after feeding an *Ae. albopictus* colony (Fig 4). This
32. very long-lived anti-saliva response observed in the donor it is possibly the result of the
33. hyperimmunization combined to the likely natural exposure to *Ae. albopictus*, a species widely
34. distributed in Italy, the country of residence of the donor at that times.
35. We also measured the IgG response to alSGE in *Ae. aegypti*-exposed mice (and vice versa),
36. as well as the response to aeSGE of the donor hyperimmune to *Ae. albopictus* saliva. In principle,
37. immune cross-reactivity between responses induced by salivary secretions of the two *Aedes* species
38. it is not surprising considering the wide overlap and degree of conservation of their salivary protein
39. repertoires [41, 42]; indeed, all mice exposed to one *Aedes* species also responded to SGE from the
40. other species (Fig 1C-D). The small number of experimental mice, the unexpectedly lower feeding
41. efficiency of *Ae. albopictus* as compared to *Ae. aegypti* (21 vs 28 mosquitoes/mice/exposure) and
42. the slightly higher protein content of aeSGE versus alSGE (10 SG/ml = 11.0 µg/ml vs 8.6 µg/ml,
43. respectively) preclude any reliable quantitative evaluation of immune cross-reactivity. Nevertheless,
44. a tentative provisional evaluation (see Methods) suggests a level of approximately 50% cross-
45. reactivity in our experimental mice. A high level of immune cross-reactivity was also observed in
46. the hyperimmune donor, who showed an almost identical response to SGEs from the two *Aedes*
47. species (Fig 4). While no previous data on mice exposed to these two mosquito species are
48. available for comparison, on the contrary, low level of immune cross-reactivity between *Ae.*
49. *albopictus* and *Ae. aegypti* SGEs has been previously reported in humans in conditions of natural
50. exposure. This was the case for individuals from Reunion Island, who were only exposed to *Ae.*
51. *albopictus*, as compared to individuals from Bolivia, only exposed to *Ae. aegypti* [63]. A likely
52. interpretation of this apparent discrepancy is that the level of immune cross-reactivity is dependent
53. on the intensity of immunization, history of exposure and responder status. This would be in
54. agreement both with the observations of Doucoure and collaborators, who found high levels of
55. cross-reactivity among individuals with high anti-saliva IgG levels [63], and with the results
56. reported here, where both the immunized mice and the human volunteer can be considered as
57. intensely exposed and high responders. Overall, besides the already mentioned limitations (small
58. number of mice, single human serum, hyperimmunization) and the apparent discrepancies, the IgG
59. responses to SGE clearly point to the effective immunization of both mice and human donor against
60. *Aedes* saliva, which allowed to proceed to the main experimental aim of our study, that is testing the
61. immunogenicity of candidate peptides and recombinant proteins.
62. In general, both peptides and full length recombinant proteins are widely used in
63. immunoassays with relative advantages and disadvantages. Recombinant proteins, carrying the
64. conformational epitopes typical of the native forms, may provide higher sensitivity but, on the other
65. side, their expression/purification can be difficult, time consuming and less reproducible. Peptides,
66. instead, can be commercially obtained by chemical synthesis with very good reproducibility and are
67. easier to be used in the field. Moreover, they have been already successfully employed to assess
68. human exposure to mosquitoes, as testified by gSG6-P1 for malaria vectors [27, 52-54] and the
69. Nterm-34kDa salivary peptide for *Aedes* vectors [35, 38]. Guided by B-cell epitope prediction
70. software, we designed five peptides on the culicine-specific 34k1, 34k2 and 62k1 *Ae. albopictus*
71. salivary proteins. The peptides were designed on the N- and/or C-terminal protein regions, which
72. are more likely to be exposed on protein surfaces and therefore visible to the immune system; this
73. was certainly the case for alb34k2-P2 and alb34k2-P3, as indicated by mapping the peptides on the
74. crystal structure of the *Ae. albopictus* 34k2 protein (P. Gabrieli and F. Forneris, personal
75. communication). However, none of these peptides appeared immunogenic to mice, and this was
76. especially surprising for alb34k1-P1 which is the orthologue of Nterm-34kDa [35], although the
77. two peptides show a certain degree of divergency, since they share 12 over 19 amino acid residues
78. with a three amino acid insertion in the *Ae. albopictus* protein. We cannot provide a clear and
79. convincing explanation for this failure: perhaps the fact that we did not use for peptide design also
80. T-cell epitope prediction software as in previous selection strategies [27, 35] may have contributed,
81. or there may be some other technical reason that we could not identify despite the several efforts.
82. Nevertheless, we report here these negative results because we believe this may represent anyway a
83. useful information for others working in the field and, overall, we should point out that, although
84. these peptides appeared not antigenic to mice, no conclusions can be drawn concerning their
85. potential antigenicity to humans.
86. The main finding of our study is certainly linked to the specific IgG responses to the al34k2
87. and ae34k2 recombinant proteins observed in immunized mice and in the single human
88. hyperimmune donor. Two out of the four *Ae. albopictus*-immunized mice developed anti-al34k2
89. IgG antibodies: the response was evident only after the fourth/last exposure and stayed essentially
90. unchanged in both mice up to two months (+60) after the end of exposure. Afterwards, IgG levels
91. appeared to decrease in M10 and persisted at high level in M12 (Fig 3A). The other two mice (M9
92. and M11) did not show IgG responses to al34k2 at any time point. This may be due to the less
93. effective immunization of these mice, who also showed lower IgG responses to alSGE as compared
94. to M10 and M12, or perhaps to a limiting antigenicity of the al34k2 salivary protein. It may be also
95. possible that these mice presented specific IgM but no IgG. The available data do not allow to sort
96. this out, however, it should be emphasized that high individual variability, both in the quality and in
97. the intensity of the host response to mosquito salivary antigens, has been repeatedly observed in
98. many different studies, as exemplified by the IgG responses to the *An. gambiae* salivary proteins
99. gSG6 and cE5 measured in the same individuals highly exposed to malaria vector bites in a
100. hyperendemic area of Burkina Faso [29]. Therefore, despite the absence of IgG responses in M9
101. and M11, and also considering the small total number of mice analyzed, we believe that these
102. observations provide preliminary but promising indications on the antigenicity of al34k2. As far as
103. the *Ae. aegypti*-exposed mice are concerned, they all exhibited an intense IgG response to ae34k2
104. clearly pointing out its immunogenicity too. Also in this case the response appeared only after the
105. fourth/last exposure in three of the four mice (M5, M6 and M8); afterwards, it stayed essentially
106. unchanged up to 5 months later in M5 and M8, while appeared to gradually decrease in M6. In the
107. remaining mice (M7) the IgG response exhibited a somewhat different kinetic with a later
108. appearing, moderate growth up to 3 months (+90) and then a slight decrease (Fig 3B). Overall, we
109. can conclude that both al34k2 and ae34k2 were immunogenic to mice even though, considering the
110. number of mice showing detectable IgG responses and their intensities, the latter seems to evoke
111. stronger IgG antibody responses. However, it should be kept in mind that the unexpected lower
112. feeding efficiency of *Ae. albopictus* (21 bites/mouse/exposure) as compared to *Ae. aegypti* (28
113. bites/mouse/exposure), and the possible resulting less effective immunization, may also account at
114. least in part for the observed difference. Strikingly, despite the relatively high degree of identity
115. (62%) between the two orthologous proteins, we observed no immune cross-reactivity in the
116. exposed mice: no anti-ae34k2 IgG antibodies were detectable at any time point in the mice exposed
117. to *Ae. albopictus*, and vice versa for al34k2 and *Ae. aegypti*-exposed mice. This observation is
118. intriguing since it may represent the basis for the development of species-specific assays to assess
119. host exposure to *Ae. albopictus* or *Ae. aegypti*, respectively. Indeed, while in principle the
120. availability of a single marker allowing for the simultaneous evaluation of host exposure to *Aedes*
121. species may be desirable and practical, in same epidemiological settings species-specific assays
122. may prove very useful. For example, considering their different importance in arboviral
123. transmission, this may be the case in areas where these two species coexist or also in areas where
124. just one species is present but in sympatry with other *Aedes* species of low or no relevance for
125. arboviral transmission.
126. The availability of serum from a donor hyperimmune to *Ae. albopictus* saliva allowed to get
127. some preliminary insights into the human IgG response to al34k2. Confirming previous evidence
128. obtained by 2D-immunoblot analysis of *Ae. albopictus* SGE [55], al34k2 also appeared strongly
129. immunogenic to humans: an intense IgG response to al34k2 was evident at time point T1, shortly
130. after the donor had fed an *Ae. albopictus* colony. The same donor, at the same time point, showed
131. an IgG response of much lower intensity (~27%) to the *Ae. aegypti* ae34k2, suggesting limited
132. immune cross-reactivity in humans (Fig 4). Noteworthy, while the IgG responses to al34k2 showed
133. a marked decrease at time point T2, the antibody responses to SGE persisted at a much higher
134. extent. As already mentioned, previous studies in conditions of natural exposure indicated that
135. human IgG responses to *Aedes* saliva are short-lived [60-62]. The long persistence of the anti-saliva
136. response in the hyperimmune donor may be the results of the hyperimmunization and of the likely
137. natural exposure of the donor to bites of *Ae. albopictus*; moreover, the high inter-individual
138. variability of the anti-saliva response, even in condition of natural exposure, should be kept in mind
139. [60-62]. On the other side, the decay of the anti-al34k2 IgG responses is not surprising considering
140. that mosquito saliva is a complex mixture of hundred or more proteins, and that host antibody
141. response to these proteins is heterogenous, with some eliciting short-lived IgG responses and others
142. triggering longer-lasting antibody responses [29]. In this respect, it is important to clarify that a
143. critical property for a good serological marker of host exposure to vectors is the duration of the IgG
144. antibody response. An ideal marker should evoke a short-term response, allowing for the detection
145. of spatial and temporal variations in host exposure: this is the case for the *An. gambiae* gSG6
146. protein or the gSG6-P1 [26-33, 51, 54] and for the *Ae. aegypti* Nterm34kDa peptide [34-38]. In our
147. study the immunized mice showed a persistence of the IgG responses to al34k2 and ae34k2 for at
148. least three months after the end of exposure, with some trend to decrease afterwards, whereas the
149. single human serum analyzed here cannot provide any useful information about timing. Further
150. analyses in humans will be crucial to better understand the kinetics of decay of anti-al34k2 and
151. ae34k2 IgG responses in condition of natural exposure and clarify their suitability as serological
152. tools to detect seasonal variations of host exposure to *Aedes* mosquitoes.
153. In conclusion, we would like to point out that the Nterm34kDa peptide, the best tool
154. presently available for the serological assessment of human exposure to *Aedes* mosquito vectors, is
155. designed on the 34k1 salivary protein of *Ae. aegypti* and that 34k1 and 34k2 proteins are largely
156. divergent: they only share 32-33% amino acid identity in *Ae. albopictus* and *Ae. aegypti*,
157. respectively. This implies that the 34k2 proteins, whose expression, purification and testing are
158. reported here, represent real novel candidates. Both the mice and human samples analyzed in our
159. study provided some preliminary but certainly encouraging information on the antigenicity of the
160. al34k2 and ae34k2 proteins and on the IgG response they evoke in exposed hosts; however, it
161. should be kept in mind that this information refers to a small number of mice and a single human
162. donor in conditions of intense and repeated exposure. Measurements of the humoral response in
163. relatively large group of individuals naturally subjected to *Aedes* bites from locations with different
164. mosquito densities and/or from the same area in different seasons (high and low *Aedes* density) will
165. be essential to get a clearer idea on their suitability as reliable antigens to detect spatial and
166. temporal variations of human exposure to *Ae. albopictus* and/or *Ae. aegypti*.

# Acknowledgments

1. We wish to thank C. Rizzo for the help in setting up and optimizing immunoassay, P. Serini and M.
2. Calzetta for providing *Ae. albopictus* mosquitoes.

# References

1. 1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and 618 burden of dengue. Nature. 2013;496(7446): 504-7.

619 2. Baud D, Gubler DJ, Schaub B, Lanteri MC, Musso D. An update on Zika virus infection. Lancet. 620 2017;390(10107): 2099-109.

621 3. WHO. Global Vector Control Response 2017-2030. Geneva: World Health Organization. 2017. 622 Available from: [http://apps.who.int/iris/bitstream/10665/259205/1/9789241512978-eng.pdf.](http://apps.who.int/iris/bitstream/10665/259205/1/9789241512978-eng.pdf)

623 4. Renault P, Solet JL, Sissoko D, Balleydier E, Larrieu S, Filleul L, et al. A major epidemic of chikungunya 624 virus infection on Reunion Island, France, 2005-2006. Am J Trop Med Hyg. 2007;77(4): 727-31.

625 5. Kraemer MU, Sinka ME, Duda KA, Mylne AQ, Shearer FM, Barker CM, et al. The global distribution of 626 the arbovirus vectors Aedes aegypti and Ae. albopictus. Elife. 2015;4: e08347.

627 6. WHO. Chikungunya Fact sheets. Geneva: World Health Organization. 2017. Available from: 628 [https://www.who.int/news-room/fact-sheets/detail/chikungunya.](https://www.who.int/news-room/fact-sheets/detail/chikungunya)

629 7. Garske T, Van Kerkhove MD, Yactayo S, Ronveaux O, Lewis RF, Staples JE, et al. Yellow Fever in Africa: 630 estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS 631 Med. 2014;11(5): e1001638.

632 8. WHO. Yellow fever Fact sheets. Geneva: World Health Organization. 2018. Available from: 633 <https://www.who.int/news-room/fact-sheets/detail/yellow-fever>.

634 9. Bonizzoni M, Gasperi G, Chen X, James AA. The invasive mosquito species Aedes albopictus: current 635 knowledge and future perspectives. Trends Parasitol. 2013;29(9): 460-8.

636 10. Lounibos LP, Kramer LD. Invasiveness of Aedes aegypti and Aedes albopictus and Vectorial Capacity 637 for Chikungunya Virus. J Infect Dis. 2016;214(suppl 5): S453-S8.

638 11. Gossner CM, Ducheyne E, Schaffner F. Increased risk for autochthonous vector-borne infections 639 transmitted by Aedes albopictus in continental Europe. Euro Surveill. 2018;23(24): 1800268.

640 12. Tsetsarkin KA, McGee CE, Volk SM, Vanlandingham DL, Weaver SC, Higgs S. Epistatic roles of E2 641 glycoprotein mutations in adaption of chikungunya virus to Aedes albopictus and Ae. aegypti mosquitoes. 642 PLoS One. 2009;4(8): e6835.

643 13. Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S. A single mutation in chikungunya virus affects 644 vector specificity and epidemic potential. PLoS Pathog. 2007;3(12): e201.

645 14. Kraemer MUG, Reiner RC, Jr., Brady OJ, Messina JP, Gilbert M, Pigott DM, et al. Past and future spread 646 of the arbovirus vectors Aedes aegypti and Aedes albopictus. Nat Microbiol. 2019;4(5): 854-63.

647 15. CDC. Center for Disease Control and Prevention. Dengue Vaccine. May 3, 2019. Available from: 648 <https://www.cdc.gov/dengue/prevention/dengue-vaccine.html>.

649 16. Espana G, Yao Y, Anderson KB, Fitzpatrick MC, Smith DL, Morrison AC, et al. Model-based assessment 650 of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure. 651 PLoS Negl Trop Dis. 2019;13(7): e0007482.

652 17. Focks DA. A review of entomological sampling methods and indicators for dengue vectors. Geneva: 653 World Health Organization on behalf of the Special Programme for Research and Training in Tropical 654 Diseases. 2014. Available from: <http://www.who.int/iris/handle/10665/68575>.

655 18. Ribeiro JMC, Arcà B. From Sialomes to the Sialoverse: An Insight into Salivary Potion of Blood-Feeding 656 Insects. Adv Insect Physiol. 2009;37: 59-118.

657 19. Schwartz BS, Ribeiro JM, Goldstein MD. Anti-tick antibodies: an epidemiologic tool in Lyme disease 658 research. Am J Epidemiol. 1990;132(1): 58-66.

659 20. Doucoure S, Mouchet F, Cournil A, Le Goff G, Cornelie S, Roca Y, et al. Human antibody response to 660 Aedes aegypti saliva in an urban population in Bolivia: a new biomarker of exposure to Dengue vector bites. 661 Am J Trop Med Hyg. 2012;87(3): 504-10.

662 21. Remoue F, Cisse B, Ba F, Sokhna C, Herve JP, Boulanger D, et al. Evaluation of the antibody response 663 to Anopheles salivary antigens as a potential marker of risk of malaria. Trans R Soc Trop Med Hyg. 664 2006;100(4): 363-70.

665 22. Trevejo RT, Reeves WC. Antibody response to *Culex tarsalis* salivary gland antigens among sentinel 666 chickens in California. Am J Trop Med Hyg. 2005;72(4): 481-7.

667 23. Arcà B, Ribeiro JM. Saliva of hematophagous insects: a multifaceted toolkit. Curr Opin Insect Sci. 668 2018;29: 102-9.

669 24. Arcà B, Lombardo F, Struchiner CJ, Ribeiro JM. Anopheline salivary protein genes and gene families: 670 an evolutionary overview after the whole genome sequence of sixteen Anopheles species. BMC Genomics. 671 2017;18(1): 153.

672 25. Ribeiro JM, Mans BJ, Arcà B. An insight into the sialome of blood-feeding Nematocera. Insect Biochem 673 Mol Biol. 2010;40(11): 767-84.

674 26. Drame PM, Poinsignon A, Besnard P, Cornelie S, Le Mire J, Toto JC, et al. Human antibody responses 675 to the Anopheles salivary gSG6-P1 peptide: a novel tool for evaluating the efficacy of ITNs in malaria vector 676 control. PLoS One. 2010;5(12): e15596.

677 27. Poinsignon A, Cornelie S, Mestres-Simon M, Lanfrancotti A, Rossignol M, Boulanger D, et al. Novel 678 peptide marker corresponding to salivary protein gSG6 potentially identifies exposure to Anopheles bites. 679 PLoS One. 2008;3(6): e2472.

680 28. Proietti C, Verra F, Bretscher MT, Stone W, Kanoi BN, Balikagala B, et al. Influence of infection on 681 malaria-specific antibody dynamics in a cohort exposed to intense malaria transmission in northern Uganda. 682 Parasite Immunol. 2013;35(5-6): 164-73.

683 29. Rizzo C, Lombardo F, Ronca R, Mangano V, Sirima SB, Nebie I, et al. Differential antibody response to 684 the *Anopheles gambiae* gSG6 and cE5 salivary proteins in individuals naturally exposed to bites of malaria 685 vectors. Parasit Vectors. 2014;7(1): 549.

686 30. Rizzo C, Ronca R, Fiorentino G, Mangano VD, Sirima SB, Nebie I, et al. Wide cross-reactivity between 687 *Anopheles gambiae* and *Anopheles funestus* SG6 salivary proteins supports exploitation of gSG6 as a marker 688 of human exposure to major malaria vectors in tropical Africa. Malar J. 2011;10: 206.

689 31. Stone W, Bousema T, Jones S, Gesase S, Hashim R, Gosling R, et al. IgG responses to *Anopheles* 690 *gambiae* salivary antigen gSG6 detect variation in exposure to malaria vectors and disease risk. PLoS One. 691 2012;7(6): e40170.

692 32. Ya-Umphan P, Cerqueira D, Parker DM, Cottrell G, Poinsignon A, Remoue F, et al. Use of an Anopheles 693 Salivary Biomarker to Assess Malaria Transmission Risk Along the Thailand-Myanmar Border. J Infect Dis. 694 2017;215(3): 396-404.

695 33. Idris ZM, Chan CW, Mohammed M, Kalkoa M, Taleo G, Junker K, et al. Serological measures to assess 696 the efficacy of malaria control programme on Ambae Island, Vanuatu. Parasit Vectors. 2017;10(1): 204.

697 34. Sagna AB, Yobo MC, Elanga Ndille E, Remoue F. New Immuno-Epidemiological Biomarker of Human 698 Exposure to Aedes Vector Bites: From Concept to Applications. Trop Med Infect Dis. 2018;3(3).

699 35. Elanga Ndille E, Doucoure S, Damien G, Mouchet F, Drame PM, Cornelie S, et al. First attempt to 700 validate human IgG antibody response to Nterm-34kDa salivary peptide as biomarker for evaluating exposure 701 to Aedes aegypti bites. PLoS Negl Trop Dis. 2012;6(11): e1905.

702 36. Yobo CM, Sadia-Kacou CAM, Adja MA, Elanga-Ndille E, Sagna AB, Guindo-Coulibaly N, et al. Evaluation 703 of Human Exposure to Aedes Bites in Rubber and Palm Cultivations Using an Immunoepidemiological 704 Biomarker. Biomed Res Int. 2018;2018: 3572696.

705 37. Ndille EE, Dubot-Peres A, Doucoure S, Mouchet F, Cornelie S, Sidavong B, et al. Human IgG antibody 706 response to Aedes aegypti Nterm-34 kDa salivary peptide as an indicator to identify areas at high risk for 707 dengue transmission: a retrospective study in urban settings of Vientiane city, Lao PDR. Trop Med Int Health. 708 2014;19(5): 576-80.

709 38. Elanga Ndille E, Doucoure S, Poinsignon A, Mouchet F, Cornelie S, D'Ortenzio E, et al. Human IgG 710 Antibody Response to Aedes Nterm-34kDa Salivary Peptide, an Epidemiological Tool to Assess Vector Control 711 in Chikungunya and Dengue Transmission Area. PLoS Negl Trop Dis. 2016;10(12): e0005109.

712 39. Donovan MJ, Messmore AS, Scrafford DA, Sacks DL, Kamhawi S, McDowell MA. Uninfected mosquito 713 bites confer protection against infection with malaria parasites. Infect Immun. 2007;75(5): 2523-30.

714 40. Kebaier C, Voza T, Vanderberg J. Neither mosquito saliva nor immunity to saliva has a detectable 715 effect on the infectivity of Plasmodium sporozoites injected into mice. Infect Immun. 2010;78(1): 545-51.

716 41. Arcà B, Lombardo F, Francischetti IM, Pham VM, Mestres-Simon M, Andersen JF, et al. An insight into 717 the sialome of the adult female mosquito Aedes albopictus. Insect Biochem Mol Biol. 2007;37(2): 107-27.

718 42. Ribeiro JM, Arcà B, Lombardo F, Calvo E, Phan VM, Chandra PK, et al. An annotated catalogue of 719 salivary gland transcripts in the adult female mosquito, *Aedes aegypti*. BMC Genomics. 2007;8(1): 6.

720 43. Jespersen MC, Peters B, Nielsen M, Marcatili P. BepiPred-2.0: improving sequence-based B-cell 721 epitope prediction using conformational epitopes. Nucleic Acids Res. 2017;45(W1): W24-W9.

722 44. Saha S, Raghava GP. Prediction of continuous B-cell epitopes in an antigen using recurrent neural 723 network. Proteins. 2006;65(1): 40-8.

724 45. Saha S, Raghava GPS. BcePred: Prediction of continuous B-cell epitopes in antigenic sequences using 725 physico-chemical properties. In: Nicosia G, Cutello V, Bentley PJ, Timmis J, editors. Artificial Immune Systems 726 - ICARIS 2004, Lecture Notes in Computer Science. 3239: Springer, Berlin, Heidelberg; 2004. p. 197-204.

727 46. Rubinstein ND, Mayrose I, Martz E, Pupko T. Epitopia: a web-server for predicting B-cell epitopes. 728 BMC Bioinformatics. 2009;10: 287.

729 47. Rubinstein ND, Mayrose I, Pupko T. A machine-learning approach for predicting B-cell epitopes. Mol 730 Immunol. 2009;46(5): 840-7.

731 48. Kuo D, Nie M, Courey AJ. SUMO as a solubility tag and in vivo cleavage of SUMO fusion proteins with 732 Ulp1. Methods Mol Biol. 2014;1177: 71-80.

733 49. Studier FW. Protein production by auto-induction in high density shaking cultures. Protein Expr Purif. 734 2005;41(1): 207-34.

735 50. Gasteiger E, Hoogland C, Gattiker A, Duvaud Se, Wilkins MR, Appel RD, et al. Protein Identification 736 and Analysis Tools on the ExPASy Server. In: Walker JM, editor. The Proteomics Protocols Handbook. Totowa, 737 NJ: Humana Press; 2005. p. 571-607.

738 51. Rizzo C, Ronca R, Fiorentino G, Verra F, Mangano V, Poinsignon A, et al. Humoral response to the 739 *Anopheles gambiae* salivary protein gSG6: a serological indicator of exposure to Afrotropical malaria vectors. 740 PLoS One. 2011;6(3): e17980.

741 52. Drame PM, Poinsignon A, Besnard P, Le Mire J, Dos-Santos MA, Sow CS, et al. Human antibody 742 response to Anopheles gambiae saliva: an immuno-epidemiological biomarker to evaluate the efficacy of 743 insecticide-treated nets in malaria vector control. Am J Trop Med Hyg. 2010;83(1): 115-21.

744 53. Drame PM, Poinsignon A, Dechavanne C, Cottrell G, Farce M, Ladekpo R, et al. Specific antibodies to 745 Anopheles gSG6-P1 salivary peptide to assess early childhood exposure to malaria vector bites. Malar J. 746 2015;14: 285.

747 54. Poinsignon A, Cornelie S, Ba F, Boulanger D, Sow C, Rossignol M, et al. Human IgG response to a 748 salivary peptide, gSG6-P1, as a new immuno-epidemiological tool for evaluating low-level exposure to 749 Anopheles bites. Malar J. 2009;8: 198.

750 55. Doucoure S, Cornelie S, Patramool S, Mouchet F, Demettre E, Seveno M, et al. First screening of Aedes 751 albopictus immunogenic salivary proteins. Insect Mol Biol. 2013;22(4): 411-23.

752 56. Surasombatpattana P, Ekchariyawat P, Hamel R, Patramool S, Thongrungkiat S, Denizot M, et al. 753 Aedes aegypti saliva contains a prominent 34-kDa protein that strongly enhances dengue virus replication in 754 human keratinocytes. J Invest Dermatol. 2014;134(1): 281-4.

755 57. Sri-In C, Weng SC, Chen WY, Wu-Hsieh BA, Tu WC, Shiao SH. A salivary protein of Aedes aegypti 756 promotes dengue-2 virus replication and transmission. Insect Biochem Mol Biol. 2019;111: 103181.

757 58. Ribeiro JM, Charlab R, Pham VM, Garfield M, Valenzuela JG. An insight into the salivary transcriptome 758 and proteome of the adult female mosquito Culex pipiens quinquefasciatus. Insect Biochem Mol Biol. 759 2004;34(6): 543-63.

760 59. Ribeiro JMC, Martin-Martin I, Moreira FR, Bernard KA, Calvo E. A deep insight into the male and 761 female sialotranscriptome of adult Culex tarsalis mosquitoes. Insect Biochem Mol Biol. 2018;95: 1-9.

762 60. Orlandi-Pradines E, Almeras L, Denis de Senneville L, Barbe S, Remoue F, Villard C, et al. Antibody 763 response against saliva antigens of Anopheles gambiae and Aedes aegypti in travellers in tropical Africa. 764 Microbes Infect. 2007;9(12-13): 1454-62.

765 61. Londono-Renteria B, Cardenas JC, Cardenas LD, Christofferson RC, Chisenhall DM, Wesson DM, et al. 766 Use of anti-Aedes aegypti salivary extract antibody concentration to correlate risk of vector exposure and 767 dengue transmission risk in Colombia. PLoS One. 2013;8(12): e81211.

768 62. Doucoure S, Mouchet F, Cornelie S, Drame PM, D'Ortenzio E, DeHecq JS, et al. Human antibody 769 response to Aedes albopictus salivary proteins: a potential biomarker to evaluate the efficacy of vector 770 control in an area of Chikungunya and Dengue Virus transmission. Biomed Res Int. 2014;2014: 746509.

771 63. Doucoure S, Mouchet F, Cornelie S, DeHecq JS, Rutee AH, Roca Y, et al. Evaluation of the human IgG 772 antibody response to Aedes albopictus saliva as a new specific biomarker of exposure to vector bites. PLoS 773 Negl Trop Dis. 2012;6(2): e1487.

774